Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7315)
All Articles published online
|
Publishing Process of This Article
|
Jun 28, 2020 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhou CZ, Wang RF, Lv WF, Fu YQ, Cheng DL, Zhu YJ, Hou CL, Ye XJ. Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome. World J Gastroenterol 2020; 26(24): 3472-3483 [PMID: 32655270 DOI: 10.3748/wjg.v26.i24.3472] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v26/i24/3472.htm |
| Number | Citing Articles |
| 1 |
Sai Li, Yong Li, Chunhui Zhou, Haiping Li, Changyong Chen, Changli Peng, Tianming Wang, Fei Liu, Juxiong Xiao, Liangrong Shi. Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis. CardioVascular and Interventional Radiology 2023; 46(7): 931 doi: 10.1007/s00270-023-03451-9
|
| 2 |
Lina Hountondji, Dimitri Pureur, Melchior Chabannes, Sophie Felix, Thierry Thévenot. Transjugular Intrahepatic Portosystemic Shunt is effective to treat portal hypertension due to sinusoidal obstructive syndrome. Clinics and Research in Hepatology and Gastroenterology 2023; 47(8): 102201 doi: 10.1016/j.clinre.2023.102201
|
| 3 |
Marta Magaz, Juan Carlos García-Pagán. Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt. Hepatology International 2021; 15(3): 568 doi: 10.1007/s12072-021-10166-x
|
| 4 |
Qianxin Huang, Qingqiao Zhang, Hao Xu, Maoheng Zu, Jinchang Xiao, Bin Shen. Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. European Journal of Gastroenterology & Hepatology 2023; 35(4): 445 doi: 10.1097/MEG.0000000000002509
|
| 5 |
Yanxia Fei, Yanhua Peng, Huiping Sun, Shuangfa Zou, Jinfeng Yang. Portal Hypertension - Recent Advances. 2021; doi: 10.5772/intechopen.96370
|
| 6 |
Matthew D. Gosse, Dustin E. Bosch. Congestive Hepatopathy: A Case of Fontan-Associated Liver Disease and Review of Literature. AJSP: Reviews and Reports 2022; 27(6): 241 doi: 10.1097/PCR.0000000000000534
|
| 7 |
Tongmin Huang, Xingfen Zhang, Kun Yan, Dandi Lou, Yujing He, Senjie Dai, Dingcheng Zheng, Ping Chen, Feng Wu, Lihu Gu. Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study. European Journal of Gastroenterology & Hepatology 2023; 35(9): 1004 doi: 10.1097/MEG.0000000000002591
|